The estimated Net Worth of Russell P Wilson is at least $798 ezer dollars as of 31 January 2015. Russell Wilson owns over 5,050 units of Novavax stock worth over $798,100 and over the last 13 years Russell sold NVAX stock worth over $0.
Russell has made over 3 trades of the Novavax stock since 2014, according to the Form 4 filled with the SEC. Most recently Russell bought 5,050 units of NVAX stock worth $11,514 on 31 January 2015.
The largest trade Russell's ever made was buying 5,050 units of Novavax stock on 31 January 2015 worth over $11,514. On average, Russell trades about 2,134 units every 52 days since 2012. As of 31 January 2015 Russell still owns at least 64,939 units of Novavax stock.
You can see the complete history of Russell Wilson stock trades at the bottom of the page.
Russell's mailing address filed with the SEC is 9920 BELWARD CAMPUS DRIVE, , ROCKVILLE, MD, 20850.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi és Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: